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Abstract
Congenital sucrase-isomaltase deficiency is an example of a 
disease in which mutant phenotypes generate transport- 
incompetent molecules. Here, we analyze at the molecular 
level a phenotype of congenital sucrase-isomaltase defi­
ciency in which sucrase-isomaltase (SI) is not transported to 
the brush border membrane but accumulates as a mannose- 
rich precursor in the endoplasmic reticulum (ER), ER- 
Golgi intermediate compartment, and the ds-Golgi, where 
it is finally degraded. A 6-kb clone containing the full- 
length cDNA encoding SI was isolated from the patient’s 
intestinal tissue and from normal controls. Sequencing of 
the cDNA revealed a single mutation, A/C at nucleotide 
3298 in the coding region of the sucrase subunit of the en­
zyme complex. The mutation leads to a substitution of the 
glutamine residue by a proline at amino acid 1098 (Q1098P), 
The Q1098P mutation lies in a region that is highly con­
served between sucrase and isomaltase from different spe­
cies and several other structurally and functionally related 
proteins.
This is the first report that characterizes a point mutation 
in the SI gene that is responsible for the transport incom­
petence of SI and for its retention between the ER and 
the Golgi. (J. Clin. Invest. 1996. 97:633-641.) Key words: 
ERGIC-53 • intestine • processing • quality control • retention
Introduction
The highly organized cascade of processing and modification 
events along the biosynthetic pathway of secretory and mem­
brane proteins has led to the general concept of compartmen- 
talization of the cell into structurally and functionally distinct 
organelles (1-4). Conformational modifications of membrane 
and secretory proteins commence already during their translo-
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cation across the endoplasmic reticulum (ER)1 membrane and 
continue in the ER  lumen (4-6). Among the most important 
modifications are those elicited by cotranslational glycosyla- 
tion, inter- or intramolecular disulfide bond formation, and 
subunit assembly known as oligomerization (5, 7, 8). These 
events are considered to be rate limiting along the exocytic 
pathway. However, modifications in the Golgi, such as acquisi­
tion of a complex type of oligosaccharides, have bêen fre­
quently reported to confer effects also on the transport kinet­
ics of proteins to the cell surface and secretion into the 
external milieu (9-12). Analysis and identification of the vari­
ous steps of the secretory pathway and dissection of the molec­
ular mechanisms adequate for efficient transport of membrane 
and secretory proteins to the cell surface have been success­
fully investigated in naturally occurring mutant phenotypes of 
proteins with impaired targeting (for review see reference 13).
Congenital sucrase-isomaltase deficiency (CSID) has been 
used to characterize various steps in the biosynthesis, trans­
port, and sorting of sucrase-isomaltase (SI) as a model for cell 
surface membrane proteins (14-17). CSID is an autosomal re­
cessive disorder of the small intestine that is clinically mani­
fested as a watery osmotic-fermentative diarrhea upon inges­
tion of di- and oligosaccharides. Epithelial cells of patients 
with this disease lack the sucrase activity of the enzyme SI, 
while the isomaltase activity can vary from absent to practi­
cally normal.
SI is a type II integral membrane glycoprotein that is exclu­
sively expressed in the small intestinal microvillar membrane 
(18) and is responsible for the terminal digestion of dietary su­
crose and starch (for review see reference 19). The glycopro­
tein comprises two subunits that are highly homologous and 
are thought to be derived from the same ancestral gene (20). 
These two subunits are associated with each other by strong 
noncovalent, ionic interactions (19,21). SI is synthesized in the 
rough ER as a single chain mannose-rich precursor comprising 
both subunits (pro-SIh, 210 kD) (22), It is transported to the 
Golgi apparatus at a relatively slow rate and does not form ho­
modimers before ER exit (11). The strong homologies be­
tween the two main domains suggest that quasi-dimers or 
pseudo-dimers (8) are formed, which are presumably sufficient 
for acquisition of transport competence. After modification of 
the N-linked glycans and O-glycosylation, SI is sorted to the
1. Abbreviations used in this paper: AMV, avian myeloblastosis virus; 
ApN, aminopeptidase N; CSID, congenital sucrase-isomaltase defi­
ciency; Endo F/GF; Endo-iV-acetylglucosaminidase F/glycopeptidase 
F; Endo H, Endo-N-acetylglucosaminidase H; ER, endoplasmic retic­
ulum; ERGIC, ER-Golgi intermediate compartment; LPH, lactase- 
phlorizin hydrolase; SI, sucrase-isomaltase.
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apical membrane and cleaved in situ by lumenal pancreatic 
proteases to its two active subunits, sucrase and isomaltase 
(22, 23).
The molecular basis of CSID is still not elucidated. H ow­
ever, it has been proposed that different molecular defects or 
mutations in the SI gene are responsible for CSID (24). This 
hypothesis has been strongly supported by the analysis of sev­
eral cases of CSID, which has led to the identification of five 
different phenotypes of SI (14 ,17). Phenotypes I and II, for in­
stance, are characterized by an intracellular accumulation of 
marinose-rich SI in the E R  and the Golgi, respectively. In phe­
notype III an enzymatically inactive, but transport-competent, 
SI is expressed. Phenotype IV expresses a partially folded, 
mannose-rich SI m olecule that is missorted to the basolateral 
membrane. Finally, phenotype V  reveals an SI species that un­
dergoes intracellular degradation leaving behind the isomal­
tase subunit that is correctly targeted to the brush border 
membrane. In this paper we analyzed a biopsy specimen of 
CSID phenotype II and demonstrated that SI is located in the 
ER, the intermediate compartment and the cis-Golgi. We 
show for the first time that a single point mutation is responsi­
ble for the impaired transport behavior o f SI.
Methods
Antibodies. Four epitope-specific mAbs directed against sucrase, iso­
maltase, or SI were used (25). These antibodies were products of the 
following hybridomas: HBB 1/691, HBB 2/614, HBB 2/219, and HBB 
3/705. mAb anti-human lactase-phlorizin hydrolase (mAb anti-LPH) 
and mAb anti-human aminopeptidase N (mAb anti-ApN) were 
products of hybridomas HBB 1/909 and HBB 3/153, respectively (25). 
mAb anti-ER-GoIgi intermediate compartment-53 (anti-ERGIC- 
53) was a product of hybridoma Gl/93 (26). All mAbs were gener­
ously provided by Dr. H. P. Hauri (Biocenter, Basel, Switzerland) 
and Dr. E. E. Sterchi (University of Bern, Bern, Switzerland).
Cell lines. Caco-2 cells (ATCC HTB-37) were cultured in Dul- 
becco’s modified Eagle’s medium (DME) supplemented with 20% 
heat-inactivated fetal calf serum (FCS), 1% nonessential amino acids 
and antibiotics (all from GIBCO BRL, Gaithersburg, MD). Monkey 
kidney COS-1 (ATCC CRL-1650) cells were cultured in DME sup­
plemented with 10% FCS and antibiotics. All cell lines were cultured 
at 37°C in a humidified 5% C 0 2 incubator.
Processing of biopsy samples. The patient with CSID had a life­
long history of abdominal pain, cramps, and osmotic diarrhea upon 
ingestion of sucrose. CSID was assessed by the breath hydrogen test 
and by sucrose tolerance test. CSID was further confirmed by enzyme 
activity measurements of sucrase and isomaltase in intestinal biopsy 
homogenates (27). Control intestinal tissue was taken from patients 
screened for diagnostic purposes other than CSID. Peroral suction in­
testinal biopsy samples from CSID and controls were taken from the 
upper jejunum and were histologically normal. Five biopsy samples 
were obtained from each patient and immediately processed as fol­
lows. One sample was cut into small pieces and fixed for immunoelec- 
tronmicroscopy (see later). One sample was frozen in liquid nitrogen 
for RNA preparation. Three samples were biosynthetically labeled in 
organ tissue culture dishes (Falcon Division, Becton Dickinson, Lin­
coln Park, NJ) on stainless steel grids according to Naim et al. (28). 
Here, the tissue was labeled continuously with 150 |mCi of [35S]me- 
thionine (//w2s-[35S]methionine, >  1,000 |j-Ci/mmol; ICN Biomedi­
cals, Inc., Carson, CA) for 0.5, 4, or 18 h. After the labeling periods, 
the specimens were washed three times in RPMI 1640 (GIBCO BRL) 
and homogenized at 4°C with a Teflon glass homogenizer in 1 ml of 
homogenization buffer (25 mM Tris-HCl, 50 mM NaCl, pH 8.1), and 
a cocktail of protease inhibitors containing 1 mM PMSF, 1 (xg/ml pep- 
statin, 5 jjLg/ml leupeptin, 17.4 i-Lg/ml benzamidine, and 1 jjLg/ml apro-
tinin (all from Sigma Immunochemicals, St. Louis, MO). The homo­
genates were either further processed directly for immunopréci­
pitation or kept frozen at -20°C until use.
Synthesis and construction ofcDNA encoding pro-Slfrom Caco-2 
cells and from tissue o f  control individuals and CSID patients. Re­
agents and methods for routine recombinant DNA techniques and 
PCR were as described previously (29, 30). Cloning of the SI cDNA 
from the patient’s mucosal cells, control biopsies, and Caco-2 cells 
followed a similar strategy. Total RNA isolation and cDNA synthesis 
were performed as described by Moolenaar et al. (31). Total RNA 
was isolated from postconfluent Caco-2 cells using the guanidinium- 
isothiocyanate method (32). Randomly primed cDNA was synthe­
sized from 10 fig total RNA by avian myeloblastosis virus (AMV) 
reverse transcriptase (AMV-RT; Boehringer Mannheim Corp., Indi­
anapolis, IN). mRNA was incubated for 60 min at 37°C in 50 mM 
Tris/HCl (pH 8.3), 40 mM KC1, 6 mM MgCl2, 2.5 mM DTT, 1 mM 
dNTP (Boehringer Mannheim Corp.) in the presence of 200 ng ran­
dom primers and 25 U AMV-RT. The negative control underwent 
the same procedure, only AMV-RT was excluded from the reaction 
mixture. For each PCR reaction 1/10 (2 fxl) of the reaction mixture 
was used as a template. PCR reactions were performed as described 
by Innis et al. (33) with minor modifications. Briefly, cDNA tem­
plates were amplified in a total volume of 100 fjul containing, 10 mM 
Tris/HCl (pH 8.3), 25 mM KC1, 1.5 mM MgCl2, 140 mM of each 
dNTP, 700 nM of primer, and 2 U of Taq polymerase (Boehringer 
Mannheim Corp.). Double-stranded DNA was dissociated at 94°C 
for 45 s, the annealing step was at 55°C for 1 min, and the extension 
step was at 70°C for 1.5 min. The reactions were subjected to 30 cycles 
of amplification, Some of the primers used in the PCR reactions were 
designed based on the published sequences of the rabbit and human 
SI cDNA (34,35). Table I shows the position of these primers within 
the SI cDNA. The products of two independent PCR reactions were 
directly or after cloning into pGEM4Z sequenced with a DNA se­
quencing kit according to the instructions of the manufacturer (Se- 
quenase V. 2.0; United States Biochemical Corp., Cleveland, OH).
The various D N A  fragments of wild-type SI cDNA were li­
gated together and cloned into the expression vector pCB7 (36) 
to generate the plasmid phSI encoding wild-type pro-SL Se­
quencing of the D N A  fragments obtained by PCR from the 
CSID tissue revealed a single mutation A/C at nucleotide 3298. 
This mutation was found in the PCR product encompassing nu­
cleotides 2967-4201. A 619-bp (Ncol-Apal) fragment containing 
this mutation was purified and exchanged with its counterpart in
Table L Oligonucleotides Used to Synthesize Various cD N As  
by PCR
DNA fragment (bp)* Primers (5'-3f direction)
29-695 CCGGGTACCAGCCTTATCCAAGTCTG
TGAGATCTGTAAGTACTGGTCA
652-1366 GC ATTGGTCCCTT AGTGT AC
ATCCACACATGTTGTGTGTT
1299-2066 ATAGGTCGACGTGCCAATGG
CTGCCTTGATGATTTAACCA
1952-3139 GATGCAACTTGGGGCATTT
GGTACTTCATATCTCTTCTT
2967-4201 GCTCGCTATTCATCCATGGG
G ATG G CTC ATTC AT ATC A AT
4071-4923 TCCAGAGCTCATGTAGCTTTC
GTACTGGGGTAACCATAAATGCT
4876-5555 TATTCAAGCAGTTCTTATGG
TGTAAGTGCTGTGAAACTT
*bp numbering according to Green et al. (35).
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the wild-type phSI plasmid. The generated plasmid was denoted 
phSIa/c.
Transfection and metabolic labeling of COS-1 cells. COS-1 cells 
were either transfected by the DEAE-dextran method as described 
by Naim et al. (29) or via electroporation in a gene puiser (Bio-Rad 
Laboratories, Richmond, CA): a 0.4-cm cuvette containing 200 |xl ice- 
cold PBS with 1.5 million cells and 10 jxg DNA was exposed to 0.3 kV 
and 125 jxF. Transiently transfected COS-1 cells were metabolically 
labeled with 80 juuCi L-[35S]methionine (ICN Biomedicals, Inc.) as de­
scribed by Naim et al. (29). After the labeling period, the cells were 
washed and stored at —70°C until use.
Immunoprécipitation. Homogenates of biosynthetically labeled 
biopsy specimens were lysed on ice by addition of Triton X-100 and 
sodium deoxycholate to final concentrations of 0.5% each (28). Bio- 
synthetically labeled transfected COS-1 cells were lysed at 4°C for 1 h 
in lysis buffer (25 mM Tris-HCl, pH 8.0, 50 mM NaCI, 0.5% Triton 
X-100, 0.5% sodium deoxycholate, and a mixture of prolease inhibi­
tors containing 1 mM PMSF, 1 (xg/ml pepstatin, 5 jA g/m ! leupeptin, 
17,4 |JLg/mI benzamidine, and 1 jxg/ml aprotinin). Usually 1 ml ice-cold 
lysis buffer was used for each 100-mm culture dish ( ~  2-4 X 10fl 
cells). Detergent extracts of cells or biopsy samples were centrifuged 
for 1. h at 100,000 g at 4°C and the supernatants were immunoprecipi- 
tated as described by Naim et al. (17,22,28,29), Four epitope-specific 
mAbs directed against sucrase, isomaltase, or SI were used (25). 
These antibodies were used in the form of ascites. Usually, 0.5-1 p.1 
ascites was used for each immunoprécipitation, For epitope mapping 
sludies with four mAbs directed against SI the extracts of biopsy sam­
ples were divided into equal aliquots and each aliquot was immuno- 
precipitated with a different antibody.
Immunofluorescence. Cellular localization of expressed proteins 
in COS-1 cells was studied with cells grown on coverslips. Cells were 
fixed with 3% paraformaldehyde and immunolabeling was carried 
out after 0.1% Triton X-100 permeabilization, using mAb anli-SI 
(HBB1/614) (1:1,000) and mAb anti~ERGIC~53 (Gl/93) (1:100) as 
the primary antibodies. The secondary antibodies used FITC-conju- 
gated goat anti-mouse or anti-rabbit IgG (1:100), Texas red-conju­
gated goat anti-mouse or anti-rabbit IgG (1:200) (all were from Boe­
hringer Mannheim Corp.). Cell surface localization of proteins was 
assessed in transfected cells that were incubated on ice with the pri­
mary antibody before fixation and without incubation with Triton 
X-100. The cells were visualized with a confocal laser microscope us­
ing a double channel for F1TC and Texas red and/or with a routine 
fluorescence microscope.
Immunoelectron microscopy. Biopsy samples were cut into small 
pieces and fixed in a mixture of 2% formaldehyde and 0.1 % glutaral- 
dehyde for 1 h at room temperature. They were then stored in 2% 
formaldehyde until use. Cryosectioning and immunolabeling with 
anti-SI, anti-ERGIC-53, and protein A-goId were performed as de­
scribed previously (26, 37).
Other procedures. SDS-PAGE was performed according to the 
method of Laemmli (38). High molecular weight markers from Sigma 
Immunochemicals were used as a reference. Treatment of immuno- 
precipitates with Endo-N-acetylglucosaminidase H (Endo H), Endo- 
Af-acetylglucosaminidase F/glycopeptidase F (Endo F/GF, afso known 
as PNGase F) (both from Boehringer Mannheim Corp.) was done as 
described before (28).
Results
Initial assessment of CSID in the patient was achieved by the 
breath hydrogen test. Subsequently a biopsy specimen was 
taken from the upper jejunum and enzymatic activity measure­
ments of the disaccharidases, SI, and LPH were performed. 
Here, no activity of sucrase or isomaltase could be detected, 
while the activity of LPH was in the normal range of the con- 
trol tissue (16-32 IU/mg protein). Likewise, normal activity of 
another control brush border enzyme, ApN, was revealed in
the patient’s biopsy sample. Therefore, the results pointed to 
an enzymatic defect that is restricted to SI. Previous analyses 
of several cases of SI deficiency have demonstrated that SI is 
synthesized as in normal controls, but is not correctly pro­
cessed or transported along the secretory pathway ('14,17). We 
therefore set out to analyze the biosynthesis and processing of 
SI in the patient’s tissue. Metabolic labeling of biopsy samples 
and immunoprécipitation of the detergent extracts with four 
different epitope-specific monoclonal anti-SI antibodies re­
vealed after 30 min of labeling an Endo H-sensitive 210-kD 
polypeptide that corresponds to mannose-rich pro-Sf (Fig. 1, 
lanes 1-3). This polypeptide remained the predominantly la­
beled species after 4 and 18 h of labeling (Fig. 1, lanes 4 -9 ) .  In 
the control biopsy specimen, by contrast, the Endo H-sensitive 
mannose-rich pro-SI (Fig. 1, lanes 10-12) was processed to a 
complex glycosylated Endo H-resistant form after 4 h of labeling 
(Fig. 1, lanes 13-15). When comparing the metabolic labeling 
intensity of the patient’s material after 4 and 18 h of labeling, no 
increase is observed as compared with the control (Fig. 1, lanes 
4-6 and 7-9 vs. lanes 10-12 and 13-15). From these data we 
conclude that no processing of the patient’s SI in the Golgi ap­
paratus has occurred and that the protein is finally degraded.
To determine whether the impaired processing is the con­
sequence of general cellular defect or is restricted to SI, the 
transport of other brush border proteins was investigated. 
ApN and LPH were synthesized and processed in the patient's 
intestinal cells in a fashion similar to control cells (Fig. 2, lanes 
1-8),  Thus, within 1 h of chase ApN was detected in the pa­
tient’s biopsy sample as an Endo H-sensitive mannose-rich 
130-kD polypeptide, which was converted into an Endo 
H-resistant 160-kD polypeptide after 20 h of chase (Fig. 2, 
lanes 3 and 4). Similarly no changes in the biosynthetic pattern 
of LPH could be observed. Here, LPH was synthesized as a 
215-kD mannose-rich species that was cleaved intracellularly 
to the mature 160-kD polypeptide (Fig, 2, lanes 7 and 8). 
Therefore, the failure of mannose-rich SI to mature to an 
Endo H resistant species is indeed restricted to this molecule 
and is not the result of a general cellular defect since two con­
trol proteins, ApN and LPH, were processed to their mature 
forms and transported normally in the patient’s tissue.
CSID Control
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Figure 1. Molecular forms of SI in CSID and in normal control. Bi­
opsy samples from a patient with CSID (lanes 7-9) and normal con­
trol (Janes 10-15) were biosynthetically labeled for the indicated 
times with [35S]methionine, The specimens were homogenized, solu­
bilized, and immunoprecipitated with monoclonal anti-SI antibodies. 
The immunoprecipitates were subjected to SDS-PAGE on 5% slab 
gels without treatment (lanes 1,4, 7, 70, and 13) or after Endo H 
(lanes 2,5, 8,11, and 14) or Endo F (lanes 3, 6y 9, i2, and 15) treat­
ment. Gels were analyzed by fluorography.
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Figure 2. Biosynthesis of the control brush border glycoproteins in 
CSID and normal control. After the immunoprécipitations with mAb 
anti-ST in Fig. 1, the supernatant? depleted from SI were immunopre- 
cipitated sequentially with mAb anti-ApN (lanes 1-4) or mAb anti- 
LPH (lanes 5-8). The immunoprecipilates were analyzed by SDS- 
PAGE on 5% slab gels without treatment (lanes i ,  3 ,5, and 7) or af­
ter Endo H (lanes 2 ,4> 6, and 8) treatment.
Since SI is synthesized at almost normal levels in the pa­
tient’s tissue but does not mature, we wanted to determine the 
subcellular localization of SI in the patient’s epithelial cells. 
Here, ultrathin cryosections of the patient’s tissue were incu­
bated with monoclonal anti-SI antibodies followed by protein 
A-gold. The subcellular localization was finally assessed by 
electron microscopy (Fig. 3). While most of the labeling in the 
control intestinal cells was confined to the brush border mem­
brane, no labeling of the brush border membrane in the pa­
tient’s tissue could be detected (Fig. 3, A  and B). Instead, in­
tense labeling of the ER and Golgi cisternae was observed in 
the patient’s tissue (Fig. 3 D ) t while the Golgi apparatus and 
the ER of the control were weakly labeled (Fig. 3 C). The lat­
ter case reflects the normal steady state situation in biopsy 
samples (14). Finally, both specimens, the patient’s as well as 
the control’s, did not show any labeling of the basolateral 
membrane.
The SI labeling in the patient’s cells was visible on one side 
of the Golgi (Fig. 3 £), arrows) and corresponds most likely to 
the c/s-Golgi and ERGIC. This is based on the labeling pattern 
obtained when biopsy samples are labeled with antibodies 
against ERGIC-53, a marker of the czs-Golgi as well as ER­
GIC (Fig. 4). It should be noted that in the patient’s biopsy 
material more label was observed for ERGIC-53 than in the 
control biopsies (compare Fig. 4, A  and B). In addition, ER- 
GIC-53 was also observed in the cisternae on one side of the 
GoJgi apparatus in contrast to control biopsies where only a tu- 
bulo-vesicular structure on one side of the Golgi was labeled 
(Fig. 4 A\ reference 26). Based on morphological criteria we 
conclude that the labeling of ERGIC-53 in the patient’s biopsy 
coincides with the label of SI (compare Figs. 3 D  and 4 B ), al­
though a direct double labeling of SI and ERGIC-53 proteins 
could not be performed. The antibodies used to detect these 
proteins are both mAbs and these are difficult to combine in 
im mu nogold double staining experiments. Control experi­
ments using antibodies against the brush border glycoproteins 
LPH and ApN demonstrated localization of these proteins in 
the apical membrane (not shown).
Altogether, the data demonstrate that in the patient’s bi­
opsy the SI molecule has egressed the ER and is arrested in an
ERGIC-53-positive, dy-Golgi compartment where it is finally 
degraded. The phenotype therefore resembles phenotype II of 
CSID described previously (17).
It is likely that the transport block of SI in the ERGIC,cis- 
Golgi, and ER as well as the persistence as a mannose-rich 
polypeptide are the consequence of structural alterations in 
the SI molecule. To examine this possibility, we performed 
epitope mapping using four different epitope-specific mono­
clonal anti-SI antibodies, HBB 2/614, HBB 2/219, HBB 1/691, 
and HBB 3/705. Except for mAb HBB1/691 all other antibod­
ies were able to recognize epitopes on mutant SI (not shown). 
The results imply that the epitope of HBB 1/619 did not ma­
ture in the patient’s SI and was altered. Drastic alterations in 
the protein folding of SI did not presumably take place, since 
three out of four antibodies have recognized the mutant SI.
To analyze the molecular defects in this phenotype, we 
cloned the full-length cDNA encoding wild-type SI from 
Caco-2 cells and from the patient’s biopsy sample. Construc­
tion of full-length cDNA encoding wild-type SI was performed 
by combining two approaches. The first used conventional 
screening of a Xgt-11 expression library made from the colon 
carcinoma cell line, Caco-2. Here, a clone comprising 1486 bp 
from nucleotides 550 to 2036 (base pair numbering according 
to Green et al. [35]) and covering almost 50% of the isomal­
tase subunit was isolated. This clone was denoted IM21.1 
(Lacey, S.W., unpublished observations). In the second ap­
proach we made use of the published sequences of rabbit and 
human SI (20, 34). Many oligonucleotides were designed and 
used to amplify SI DNA fragments using RT-PCR on RNA 
extracted from Caco-2 cells or biopsy samples. These frag­
ments and the IM21.1 clone were ligated together to generate 
the full-length pro-SI cDNA. Sequencing of this clone re­
vealed two nucleotide differences versus the published se­
quence (34). These differences are not due to PCR artifacts, as 
assessed by sequencing of PCR products of two independent 
PCR reactions. One difference is A/G at nucleotide 4001 
which represents a silent mutation. The second variation, a 
C/G at nucleotide 3612, leads to a glutamic acid instead of 
glutamine at amino acid 1203 in the sucrase subunit. Compari­
son with the amino acid sequences of rat and rabbit and our 
patient’s (see below) sucrase subunits revealed also a glutamic 
acid residue at this particular position. Moreover, the human 
and rabbit isomaltase also contained a glutamic acid in the cor­
responding homologous stretch. Therefore, it is likely that the 
glutamine/glutamic acid exchange represents a polymorphism 
in the published sequence. To test the full-length cDNA, it was 
cloned into the pCB7 expression vector and transiently ex­
pressed in COS-1 cells. Metabolic labeling of these cells 
showed that SI is processed as in normal control samples (Fig.
5, lanes 1-3, compare with Fig. 1, lanes 10-15). Also, when ex­
pressed in COS-1 cells, cell surface expression could be ob­
served (Fig. 6, A  and B).
To isolate a full-length SI cDNA encoding SI in the CSID 
tissue, a similar strategy was followed as for wild-type SI. The 
PCR products derived from two independent reactions were 
cloned and sequenced. The sequence analysis revealed one al­
teration relative to the SI cDNA cloned from Caco-2 cells. 
This alteration, A/C at nucleotide 3298, was found in the se­
quence encoding the S of the SI complex and resulted in a sub­
stitution of the glutamine 1098 by a proline (Q1098P), The 
mutation was confirmed by direct sequencing of several inde­
pendent PCR products. The wild-type sequence could never
636 Ouwendijk el a I.
v#..m
•" t  É> ■ I -M
f  ^  V f ^ 1 • *  « *  + * r m
* £ ? • £ : }  *  *  *  *  .LU .
% ^ : ■  ,  »  - * * # . ?  
Ô *  ■ :*4 ^  *  1 *  * ’& '  V • v* ^  ^
V L
*>,% r V*r>
►■; • t *
*4. **
f  -* ; 4
■;>.
1 ‘:w? k . ?  -  M "  ;  *  *  ^  : * r f* ,r  • ," -;%Èg&- J r ’ î' ' v^
I  «  > M
* ♦ > V ?É  *
i  j  
♦ V  «% *
V« ' *  • «
*#* *, : **•«5
; *  • * *  ’ r ‘ ^ K :-*>• . «  • ‘-V^ -  ' ^ -  ^
’ t f  . -  ; : . Ä  .  '
*  « \  - v » ,  • ; •  *  * • / : • ' • ' ' • #  • •
- ^  CJffiitïT?'-t** •  » ‘ * *  ** 1 ’ ‘ £ W r  r 1 ’>
r , - . . .  . < •  ■ , , .  - 1 .s  ^  Ti- "'«Vs,v: »H
’W%\< &  • ê J !
r  ► s S  1 ■• .  <
'  . -  ^ ‘- *  J
’ L L t  * ^  i r ÿ t -'*’.•!,, ..^ 7 *«*&*V$rfi-tfwL- * *"K>-
• V
'" r
‘*£wAA; f  t  ..;^M
W f  ?■ è ,  '  ; 4.Æ & W -  ‘ ^  ^  ' , -
-ïf:
■ . - i f  /  ' 1
t /  v  :-' ‘> rs ju  •; '■: W f ^ M ' C$i»a f e l ' m i
-W . ■  ^s'Pväfc« « • '  FJ
M :\iM4 y y  ■ . !i>> ' f c â ’M
Â œ . '
i ^ . # 4  ' ? %  " ’' * ' ? Æ  '•>
^  . V v'
j a * ' '  y ,■ ‘)  ' ' .  ‘*‘ i y  ?'„•*
*3, "  * ' . A f â . ^ i . ; ’ v r  ' • *■ j ->1^ * ■û-:r » • * >',«/ :, iÆ, ■■ W
• ' < -.' *<r?. ' :  * *  f ^
" ' ■
>  '•■/
• 'W
1 ? ; ^ ,  J'ÆÆ'K' -y' -  c t*V \ *  * -"JÖl ^^ ||'V.ÿf
' - /  i ' r -  '\ ^ M w Ü  M l ' .  *  ♦ Â f e v  - %  Vr . .  - * V >  ;
v ' ; / - ; ■ ' .  ’ *  *'W$R ÎMmèt' ' ^  .  f%'4Â v^f
V ' - J ' A /  • <->/ ’ * * » .  ‘V 't*  /|i- » * (■■,'■ . '-(/"l^- '>^1
■ r&mk  ' • ’ • ’  :? v -x?.l-
S; ■ ■ ;  i;:Wï|Â:^ : .^ '':> ^ i$ Ê Ë sF  ' ' ■  "l|. . 3 ; " 4 f e  ' ‘ ^
’ îl ^*yV 4 *s
Figure 3. Immunocytochemical localization of SI in CSID and normal control. SI was localized in ultrathin cryosections from a control biopsy 
{A and C), and from the patient’s biopsy (B and D )y using antibody HBB 2/614, followed by rabbit anti-mouse and protein A-10 nm gold 
staining. (A) Brush border staining observed in a control biopsy; (B) brush border staining observed in the patient’s biopsy; (C) Golgi staining 
observed in a control biopsy; and (D) Golgi staining observed in the patient’s biopsy. Note the strong accumulation of SI in this compartment. 
Also note that always a few cisternae on one side of the Golgi apparatus (arrows) are devoid of label. Bar, 0.5 \±m.
be identified, suggesting that both alleles of the SI gene con­
tain this mutation or, more likely, that one allele is not ex­
pressed.
The patient's cDNA was also cloned into the expression 
vector pCB7 and transiently expressed into COS-1 cells. 
Again, metabolically labeled COS-1 cells showed that mutant
cDNA is processed as in the patient’s biopsy (Fig. 5, lanes 4-6, 
compare with Fig. 1, lanes 1-9), In addition, localization stud­
ies showed that the patient’s SI is not expressed at the cell sur­
face of COS-1 cells, but instead accumulates intracellularly in 
the ER and ERGIC, as shown by immuno double-labeling on 
transiently transfected cells (Fig. 6, C and D).
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Figure 4. Imm un ocy to chemical localization of ERGIC-53 in CSID and normal control. Localization of ERGIC-53 was performed on ultrathin 
cryosections from a control biopsy (A) and from the patient's biopsy (B) using antibody Gl/93, followed by rabbit anti-mouse and protein A-10 
nm gold staining. (A) In the control biopsy vesicular structures on the rà-side of the Golgi apparatus are stained; (B) in contrast, in the patient’s 
biopsy the labeling is not only stronger, but also additional staining over cisternae on one side of the Golgi is observed. Morphologically the label 
coincides with that observed for SI (compare with Fig. 3 D). Bar, 0,25 jxm.
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Figure 5. Expression of wild-type and mutant SI cDNA in COS-1 
cells. COS-1 cells were transfected with phSI (lanes 1-3) or phSIa/c 
(lanes 4-6) plasmids and biosynthetically labeled with p5S]methio- 
nine for 6 h. The cell extracts were immunoprecipitated with mAb 
anti-SI. The immunoprecipitates were analyzed by SDS-PAGE on 
5% gels without treatment (lanes 1 and 4) or after Endo H (lanes 2 
and 5) or Endo F treatment (lanes 3 and 6).
Upon comparison, lysosomal a-glucosidase, Schwannioniy- 
ces occidentalis glucoamylase, sucrase, and isomaltase from 
various species share striking similarities in their amino acid 
sequences. This has led to the hypothesis that these molecules 
are derived from a common ancestral gene (39). Sequence 
comparison revealed that the mutation Q1098P in the S sub­
unit is located in a stretch of 10 amino acids that is highly ho­
mologous among sucrase (amino acids 1093-1116), isomaltase 
(amino acids 219-243), lysosomal a-glucosidase (amino acids 
239-262) and Sch. occidentalis glucoamylase (amino acids 196— 
220) (Fig. 7).
Discussion
CSID has been used to characterize various steps in the bio­
synthesis, transport, and sorting of SI as a model for cell sur­
face membrane proteins. Several different phenotypes of 
CSID have been meanwhile described (14—17). In all of these 
CSID phenotypes, the transport incompetence, aberrant enzy­
matic function, or missorting to the basolateral membrane is 
exclusively restricted to the SI molecule, ruling out a possible 
general cellular defect.
While analyses of the current and previous phenotypes at 
the subcellular and protein levels lent strong support to the hy­
pothesis that a point mutation in the cDNA of SI is responsible 
for the generation of CSID, the present data provide the first 
definite evidence that this is in fact the case. Here, we could 
characterize a point mutation in the region encoding the su­
crase subunit of the SI complex which converts a glutamine to 
a proline (Q1098P).
Therefore, the CSID malabsorption is another example of 
a clinical disorder or disease that ensues by single amino acid
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Figure 6. Immunofluorescence of wild-type and mutant SI cDNA in COS-1 cells. COS-1 cells were transfected with control SI cDNA (A and B) 
and Q1098P mutant SI cDNA (C and D). (A) Control SI can be observed in the rough ER, Golgi, and cell surface of COS-cells; (B) cell surface 
staining of control SI, see Methods for details of the procedure, (C and D) Immuno double-labeling of SÏ and ERGIC-53 in a COS cell trans­
acted with mutant SI-cDNA and observed using a confocal scanning laser microscope equipped with a Kr/Ar laser; (C) immunostaining with 
HBB 27614 anti-SI antibody in the ER and an ERGIC-53-positive compartment, note the absence of surface label (compare with A); (D) immu­
nostaining with G1/93 anti-ERGIC-53 antibody, note the structure [arrow) that is labeled both for SI (C) and ERGIC-53 (D). Bar, 15 jjim.
mutation in the polypeptide chain leading ultimately to dra­
matic alterations in the structural features, biosynthesis, post- 
translational processing, transport, and function of cell surface 
and secretory proteins. While the CSID phenotype usually 
ends up in mild malabsorption of sugars and starch, the symp­
toms of which are readily identifiable, other disorders, such as 
cystic fibrosis (40), collagen-based diseases, and familial hyper­
cholesterolemia (41), just to name a few, are more severe (for 
review see reference 13).
A rather unusual mutant form of SI is generated in CSID 
phenotype II. Here, SI exits the ER and is transported to the 
medial and tmns-GoIgi where it undergoes degradation (17). 
To our knowledge, no mammalian cell surface membrane gly­
coprotein has been so far identified that has efficiently 
egressed the ER and arrived in the Golgi cisternae where its 
transport is blocked. This strongly suggests that there are other 
criteria, in addition to the acquisition of correct folding and 
quaternary structure in the ER, that may modulate and control 
protein transport within the Golgi and to the cell surface.
The phenotype of SI described in this paper is very much 
similar to phenotype II (1.7). Analyses of the structural fea­
tures of SI in this phenotype by epitope mapping and biosyn­
thetic labeling reveal that incomplete initial folding of the SI 
precursor protein is responsible for the observed inefficient 
transport of the molecule along the secretory pathway. An ef­
fect of the oligomeric state of SI could be excluded since hu­
man SI does not dimerize and exits the ER efficiently as a mo­
nomeric molecule (8).
The most interesting aspect of phenotype II is the ability of 
SI to egress the ER to the Golgi, while still in an incompletely 
or partially folded state. The subsequent arrest and final deg­
radation of SI in a ds-Golgi compartment or in the Golgi is un­
usual and, except for SI, has not been demonstrated for an en­
dogenous protein destined for the cell surface. This is 
surprising since membrane and secretory proteins are believed 
to acquire transport competence in the ER and leave this or­
ganelle en route to their final destination.
It is generally accepted that a quality control mechanism
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human sucrase WDSWLPGFAFN DQFIQISTRLPS EY-IYGFGEVEH
ra b b it  sucrase WDSCLPGFAFN DQFIQISTRLPS BY-IYGFGEAEH
r a t  sucrase WDSSLPGFAFN DQFIQISTRLPS NY-LYGFGEV EH
human isom altase FDTSIGPLVYS DQYIiQISARLPS DY-IYGIGBQVH
ra b b it  isom altase FDSSIGPLVYS DQYLQISTRLPS EY-MYGFGEHVH
human a-g lucosidase LNTTVAPLFFA DQFLQLSTSLPS QY-ITGLAEHLS
Schw. o. glucoamylase FSTKGNPLVFS NQFIQFNSSIiPK NHVITGLGESIH
T
Figure 7. Amino acid homology around the mutated region in the pa­
tient’s SI. The amino acid sequences of normal human sucrase (32), 
rabbit sucrase (20), rat sucrase (45), human isomaltase (32), rabbit 
isomaltase (20), human lysosomal a-glucosidase (43), and Sch. occi­
dentalis glucoamylase (39) are aligned. The numbering and arrow in­
dicate the position in this highly conserved region where in the pa­
tient’s SI the Q1098P mutation is located.
exists in the ER that sorts correctly folded from malfolded pro­
teins and retains the latter In the ER (5-7,42). How could phe­
notype II of CSID be accommodated within these general 
views and concepts?
Human lysosomal a-glucosidase (43) and the yeast Sch. oc­
cidentalis glucoamylase (39) share striking homologies with 
human, rat, and rabbit S and I species and have been suggested 
to be evolved from a common ancestral gene (39). Of interest, 
the Q109SP mutation is located within a stretch of the S sub­
unit that is homologous to lysosomal a-glucosidase and Sch. 
occidentalis glucoamylase (Fig. 7). These proteins are all syn­
thesized and translocated into the ER where they are pro­
cessed to transport-competent forms and are then transported 
along, the secretory pathway to their final destinations. While 
SI is, sorted in the rram-Golgi network to the apical membrane, 
lysosomal a-glucosidase is mainly transported to the lysosomes 
after phosphorylation in the ris-Golgi and maturation in the 
medial and tmns-GolgL Sch. occidentalis glucoamylase is trans­
ported to the peripiasmic space and partially secreted into the 
exterior milieu in yeast. Obviously all three proteins share a 
common pathway from the ER to the Golgi and from there di­
verge. to different destinations. Therefore, it is conceivable that 
homologies in the polypeptide sequences should be implicated 
in the biological function or transport mechanisms common to 
all of these proteins. Consistent with this is the observation 
that the regions containing the active catalytic centers of these 
proteins have almost identical amino acid sequences (34). If 
the mutation Q1098P does not initially induce gross conforma­
tional change in the S subunit, but rather alters a subdomain 
around the mutation that is critical for the intracellular trans­
port of the SI protein or creates a retention signal, then a simi­
lar effect would be also expected if the mutation is introduced 
into the corresponding homologous regions of lysosomal 
a-glucosidase or Sch. occidentalis glucoamylase.
It is possible that in the particular case of proteins with 
multidomain structure, such as SI, complete maturation of all 
protein domains is not absolutely required for egression from 
the ER, whereby the folding of some domains may be more es­
sential or critical than others in the context of the overall con­
formation. SI is composed of two large homologous domains 
that may fold independently (Naim, H.Y., unpublished obser­
vations) and it is reasonable to assume that the presence of the 
mutation in the sucrase subunit leads to alterations in its struc­
ture while the entire isomaltase subunit remains unaffected. 
While these alterations could be tolerated by the quality con­
trol mechanism in the ER, they could be crucial for the further 
secretory pathway of SI via the Golgi to the cell surface. Re­
cent data with a temperature-sensitive mutant of vesicular sto­
matitis virus glycoprotein have proposed a quality control 
mechanism outside the ER that prevents immature vesicular 
stomatitis virus glycoprotein from traversing the Golgi (44). 
Mutant SI phenotype II may be subject to a similar mechanism 
that operates via a putative retention signal created by the 
Q1098P mutation.
We conclude that the simplest and most straight forward 
explanation for the phenotype described in this paper is that 
the mutation Q1098P has created a signal or conformational 
change in the sucrase subunit which retains the enzyme com­
plex in a cis-Golgi compartment, where it is finally degraded 
by an unknown quality control mechanism operating at a level 
beyond the ER.
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